Acute Ischemic Stroke Drugs Global Market Report 2024

The acute ischemic stroke drugs market has grown strongly in recent years. It will grow from $13.01 billion in 2023 to $13.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The expansion observed in the historical period can be attributed to several factors, including the rising incidence of stroke, government initiatives and healthcare policies, increased awareness and educational efforts, as well as strategic collaborations and partnerships. Additionally, the aging population has played a significant role in driving this growth.

The acute ischemic stroke drugs market is expected to see strong growth in the next few years. It will grow to $16.87 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be linked to various factors, including the emergence of new therapies and a robust drug pipeline, the adoption of precision medicine and personalized therapies, ongoing development in global healthcare infrastructure, a steady increase in healthcare expenditure, and the expanding role of telemedicine and remote patient monitoring. Noteworthy trends expected in the forecast period encompass advancements in thrombolytic therapies, the development of neuroprotective agents, ongoing progress in personalized medicine and biomarker research, the widespread adoption of telemedicine and remote monitoring, and an increased emphasis on collaborations and strategic partnerships.

The anticipated growth of the acute ischemic stroke drug market in the coming years is closely linked to the increasing prevalence of chronic diseases. Chronic diseases, also referred to as non-communicable diseases, are persistent conditions requiring ongoing medical care, often limiting daily activities. Leading causes of death and disability, such as heart disease, cancer, and diabetes, fall under this category. Acute ischemic stroke drugs play a crucial role in managing chronic diseases by reducing the risk of clot formation and strokes, as well as restoring blood flow to the brain. In September 2022, the World Health Organization (WHO) reported that approximately 41 million people die annually due to chronic diseases, accounting for 74% of global deaths, with 17 million individuals succumbing to these conditions before the age of 70. The projection that an estimated 164 million Americans, nearly 49% of the population, will be living with chronic illnesses by 2025 underscores the significant impact of chronic diseases on global health. Consequently, the rise in chronic disease prevalence is a key driver fueling the growth of the acute ischemic stroke drug market.

The growth trajectory of the acute ischemic stroke drugs market is further bolstered by the increasing aging population. The aging population phenomenon is characterized by a rising proportion of elderly individuals within a population. Acute ischemic stroke drugs play a vital role in this demographic by contributing to enhanced outcomes, improved quality of life, reduced disability, minimized brain damage, timely reperfusion, prevention of recurrent strokes, increased long-term survival rates, and improved potential for rehabilitation efforts. As of October 2022, the World Health Organization projected that globally, one in six people would be aged 60 or older by 2030, with the number of individuals in this age group doubling to 2.1 billion by 2050. Moreover, a June 2021 report from the UK Parliament's House of Commons Library highlighted that by 2043, the senior population in the UK is expected to rise to 24% of the total population, comprising 17.4 million people. Thus, the increasing aging population is a significant factor propelling the growth of the acute ischemic stroke drugs market.

The anticipated growth of the acute ischemic stroke drugs market in the coming years is closely tied to the increasing demand for diagnostic centers. Diagnostic centers, which assess health conditions and provide necessary treatment, play a pivotal role in the timely and accurate diagnosis crucial for effective treatment of acute ischemic stroke. As of April 2022, reports from GOV.UK, a UK-based government digital service provider, indicated that 73 diagnostic centers operated, performing an additional 30,000 tests per week in 2022. Furthermore, projections suggest an increase to 160 community diagnostic centers by 2025. This surge in demand for diagnostic centers underscores their significant role in the diagnosis and management of acute ischemic stroke, thereby driving the growth of the associated drug market.

A notable trend contributing to the evolution of the acute ischemic stroke drugs market is strategic clinical development. Major companies operating in this market are actively engaged in clinical developments as a key strategy to maintain their market position. For example, in May 2021, Biogen Inc., a US-based biotechnology company, acquired the investigational drug TMS-007 for the treatment of acute ischemic stroke. TMS-007 is positioned as a next-generation thrombolytic with an improved risk-benefit profile. Positive outcomes from the TMS-007 Phase 2a study demonstrated its efficacy in reopening blood vessels and aiding patient functional recovery without symptomatic intracranial hemorrhage.

Major players in the acute ischemic stroke drugs market are prioritizing strategic partnerships to drive revenue growth. Strategic partnerships involve collaborative alliances between independent entities to achieve shared objectives and mutual benefits. An illustrative example is the partnership between Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, and Pharmazz Inc., a U.S. biopharmaceutical company. This collaboration, announced in September 2023, aims to address the urgent demand for efficient therapies for cerebral ischemic stroke in the Indian market. The partnership introduces Sovateltide, an innovative medication designed to treat acute cerebral ischemic stroke, marking a significant development in the acute ischemic stroke drugs market.

Major companies operating in the acute ischemic stroke drugs market report are F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis, Aidoc Medical.

North America was the largest region in the acute ischemic stroke drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute ischemic stroke drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

These drugs are available in various forms, including tablets, capsules, and other formulations. Tablets, for instance, are solid unit-dose forms of medication that contain the necessary excipients. They consist of a blend of excipients and active ingredients, often in powder form, which is then compressed or pressed into a solid dosage. These medications are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with predominant use in hospitals, diagnostic centers, and other relevant applications.

The acute ischemic stroke drugs market research report provides acute ischemic stroke drugs market statistics, including acute ischemic stroke drugs industry global market size, regional shares, competitors with an acute ischemic stroke drugs market share, detailed acute ischemic stroke drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acute ischemic stroke drugs industry. This acute ischemic stroke drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute ischemic stroke drugs market consists of sales of alteplase drugs, antiplatelet drugs, clopidogrel drugs, aspirin drugs, and anticoagulant drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.